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Olga Luengo1,2* and Victòria Cardona1,2Abstract
The knowledge on molecular allergy diagnosis is continuously evolving. It is now time for the clinician to integrate
this knowledge and use it when needed to improve the accuracy of diagnosis and thus provide more precise
therapeutic and avoidance measures. This review does not intend to comprehensively analyze all the available
allergen molecules, but to provide some practical clues on use and interpretation of molecular allergy diagnosis.
The potential role of component resolved diagnosis in circumstances such as the indication of allergen immunotherapy,
pollen polysensitization, food allergy, latex allergy or anaphylaxis, is assessed. Interpreting the information provided by
molecular allergy diagnosis needs a structured approach. It is necessary to evaluate single positivities and negativities,
but also to appraise “the big picture” with perspective.
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ImmunotherapyIntroduction
Nearly 15 years after the concept of component-resolved
diagnosis was first proposed [1], the amount of know-
ledge on the molecular allergy diagnosis is continuously
evolving. Several comprehensive and extensive reviews
on component resolved diagnosis (CRD) have been pub-
lished, and their use and limitations in clinical practice
proposed [2-4]. It is now time for the clinician to inte-
grate this knowledge and use it when needed to improve
the accuracy of diagnosis and thus provide more precise
therapeutic and avoidance measures.
However, even after a thorough study of the literature
the interpretation of molecular allergy diagnosis can ini-
tially seem very complex. So, there is an unmet need for
educational programs on the use and interpretation of
molecular diagnosis. Among other initiatives, our group
has been developing a practical training program on mo-
lecular allergy diagnosis for the last four years with
attendees from Spain and Portugal. With the WAO-
ARIA-GALEN consensus on molecular diagnosis [4] as
the framework, clinicians attending these workshops
developed a proposal on “when to use CRD” in their* Correspondence: oluengo@vhebron.net
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article, unless otherwise stated.routine care that can be summarized as shown in
Table 1, which has been used as a guide for this paper.
This review does not intend to comprehensively analyze
all the available allergen molecules, or all the specific as-
pects of food, respiratory, venom or latex allergy, but to
provide some practical clues on use and interpretation
of molecular allergy diagnosis.
Indication of specific immunotherapy
The first premise for the prescription of immunotherapy
based on CRD is the assessment of IgE positivity to
genuine versus cross-reactive allergens (Figures 1 and 2).
Inhalant oligo/monosensitization
Precise identification of relevant sensitizers in the case
of pollen-allergic patient’s mono or oligosensitized to
pollens with no overlapping pollen season can be
achieved by conventional diagnosis with complete
pollen extracts. In most cases patients are sensitized to
major pollen allergens (e.g. Ole e 1, Bet v 1, Phl p 1/Phl p
5), but this may not be the case in areas with high pollen
loads, for example to olive pollen in the south of Spain,
where Ole e 7 and Ole e 9, currently considered as minor
allergens, can be the major sensitizers [5]. When prescrib-
ing specific immunotherapy in areas with high frequency of
sensitization to “minor allergens”, molecular diagnosis mayCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Proposals on when to use CRD
Circumstances of potential increase of allergy diagnosis accuracy
by CRD




o Hymenoptera venom allergy
• Anaphylaxis o Cofactor-enhanced food-dependent
anaphylaxis
o Delayed red meat anaphylaxis
o Idiopathic anaphylaxis
• Latex allergy
• Polysensitization o Pollen and plant food
• Food allergy o Risk assessment
o Identification of unanticipated
allergen triggers
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munotherapy are well standardized only for major aller-
gens. Thus, patients with sensitization to minor allergens
alone may likely not receive sufficient amounts of allergen
to achieve a successful outcome from allergen immuno-
therapy (AIT), or even worse, will experience adverse reac-
tions when the concentrations of this minor allergens
present in the extract are high [6].
Another scenario in which molecular allergy would
help to decide the correct indication of AIT wouldFigure 1 Pollen species-specific allergens.be dog dander allergy. Unlike cat allergy, almost all at-
tributable to sensitization to its major allergen Fel d 1,
the sensitization profile in case of dog allergy is more
heterogeneous [7]. In Spanish populations, Can f 5 is a
major allergen, with reported sensitizations of 70% of
dog allergic patients [8]. In our series, Can f 1, 2 and 3
are minor allergens, while Can f 5 is responsible for up
to 67% of sensitizations and, importantly 37% of our pa-
tients are not sensitized either to Can f 1, 2 or 3 but only to
Can f 5 [9]. There is a high variability between commercial
dog extracts regarding their allergen contents [10], and Can
f 5 is poorly represented. It would not seem appropriate to
indicate specific immunotherapy to dog extract in patients
monosensitized to Can f 5 until this (and possibly other)
major allergen content is guaranteed in the therapeutic
extract.Pollen polysensitization
Unfortunately mono/oligosensitized patients are more and
more scarce, at least in adults whose diagnostic complexity
increases with polysensitization [11]. Although most studies
on the relevance of CRD in complex pollen areas have been
performed in the south of Europe, polysensitization to re-
spiratory allergens is also seen in the north. This has been
shown by data of the European Community Respiratory
Health Survey (ECRHS) where 12.8% to 25.3% of patients
were polysensitized [12]. This fact has important implica-
tions when considering the prescription of immunotherapy.
Figure 2 Cross-reactive allergens. CCD: Cross-reactive carbohydrate determinants; nsLTP: Non-specific lipid transfer proteins; TLP:
thaumatin-like proteins.
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therapy with grass pollen extract has proved to be as
safe and effective for that specific allergy both in
polysensitized as in monosensitized patients [13,14], pro-
vided that the allergen extract administered matches the
patient’s most relevant sensitization.
CRD provides the information on patient specific aller-
gen sensitization to drive the selection of the immuno-
therapy extract [15], conceptually “component-resolved
treatment”. AIT would be appropriately prescribed if
sensitization to the species-specific allergens is con-
firmed, while in case of selective recognition of cross-
reactive allergens, like profilins or CCD, the indication
of AIT is arguable. Cross-reactive allergens seem to have
limited clinical relevance and their content in AIT ex-
tracts is usually not quantified. Also, in the case of
sensitization to the crude extract (SPT and/or positive
sIgE), AIT indication would be arguable if all compo-
nents are negative, since the extracts would be unlikely
to contain the sensitizing molecule.
Proving the importance of a CRD-driven immunotherapy
prescription, three prospective studies, including adult and
pediatric population, have recently shown that the incorp-
oration of CRD results alters initial AIT prescription in ap-
proximately half of the patients [16-18]. However, there is
still a gap between the current possibility of using a prede-
fined AIT preparation and the complexity of sensitization
at the population level, since the patients sIgE profiles
are highly heterogeneous depending on the geograph-
ical area and the allergen source [19,20]. Also, there is
a need to adequately evaluate in prospective studies if
CRD-guided patient selection results in improved effi-
cacy of immunotherapy.Since the first proposal of Valenta [1], few articles have
been published on how to use CRD results for the optimal
selection of immunotherapy. Very recently Douladiris et al.
have proposed a comprehensive and practical algorithm re-
garding component-resolved diagnostic work-up for pollen
AIT candidates in southern Europe [21].Hymenoptera venom immunotherapy
Molecular diagnosis can also improve the selection of
patients for hymenoptera venom immunotherapy (VIT).
The diagnosis of hymenoptera venom allergy should
be performed using non-glycosilated allergens to avoid
false-positive sIgE results due to cross-reactive carbohy-
drates. Commercially available species-specific major
allergens without CCD include Api m 1 from bee venom
(phospholipase), Ves v 1 (phospholipase) and Ves v 5
(antigen 5) from Vespula venom and Pol d 5 (antigen 5)
from Polistes dominulus venom.
Antigen 5 and phospholipase of both Vespula vulgaris
and Polistes dominulus help discriminate between true
genuine allergy and serological cross-reactivity in cases
of double positivity to traditional sIgE and venom skin
tests to both vespids [22]. Ebo et al. [23] also propose
the use of CRD with rVes v 1 and rVes v 5 in patients
with double-positive sIgE to yellow jacket and honey bee
venom, discrepant sIgE and venom skin test results, as
well as patients with negative traditional sIgE and skin
tests. Müller et al. [24] recommend the indication of
VIT to both bee and Vespula venoms in patients with
double positivity of sIgE to whole venoms, and sIgE to
Api m 1, Ves v 1 and Ves v 5. If only positive to Api m
1, VIT should be indicated only with bee venom. In
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Vespula venom would be certainly indicated. rVes v 5
has also proved to facilitate diagnosis of hymenoptera
venom allergy in patients with negative sIgE to wasp
venom [25]. In the case of honeybee venom allergy it
has been recently published that a broader panel of
CCD-free honey bee venom allergens, including rApi m
2, rApi m 3, nApi m 4, rApi m 5, and rApi m 10, im-
proves diagnostic sensitivity compared with use of rApi
m 1 alone [26].
Anaphylaxis
Cofactor-enhanced food-dependent anaphylaxis
Epidemiological data show that cofactors (exercise,
NSAIDs, alcohol, etc.) are relevant in up to 39% of all food-
dependent anaphylactic reactions in adults [27]. Wheat
dependent exercise-induced anaphylaxis (WDEIA) is the
best characterized of these syndromes, classically related to
omega-5-gliadin sensitization. Recently it has been reported
that, at least in the Mediterranean population nsLTP ac-
counts for the majority of cofactor-enhanced food allergy
(CEFA) [28,29] mainly related with vegetables, nuts and
cereals. Even in cases of WDEIA reactions, positivity to
nsLTP in the absence of omega-5-gliadin sensitization has
been reported [30]. Therefore, at least in southern Europe,
patients with a history consistent with CEFA anaphylactic
reactions should be tested for sIgE to nsLTP (mainly
Pru p 3, but also to Tri a 14) and to omega-5-gliadin.
Other underlying sensitizations may be relevant in
some populations.
Red meat delayed anaphylaxis
When evaluating a patient with a history of delayed on-
set anaphylaxis 3–6 h after ingestion of mammalian food
products (e.g., beef and pork), sIgE against galactose-α-
1,3-galactose (α-gal) should be performed [31]. Before
the identification of the allergen responsible for this syn-
drome, because of the delay of symptoms after ingestion
of meat products, the frequent negative SPT responses
and the good tolerance to other meats like turkey, these
types of anaphylaxis have been wrongly classified as idio-
pathic [32]. It has been suggested that tick bites are the
cause of IgE antibody responses to α-gal and it is recom-
mended to reassess sIgE levels every 8 to 12 months as
they tend to decrease over time, and some patients have
been able to tolerate mammalian meat again after avoid-
ing additional tick bites for 1 to 2 years [33].
Idiopathic anaphylaxis
Although idiopathic anaphylaxis involves a small pro-
portion of patients with anaphylaxis, the clinical impli-
cations are highly significant. The inability to identify a
cause prevents from usual anaphylaxis interventionssuch as avoidance measures, specific education and
modification of risk.
To date, only one study has addressed the question
whether the ISAC allergy array would add diagnostic
value in patients with idiopathic anaphylaxis. Heaps
et al. [34] performed an ISAC-103 test (Thermo
Fischer Scientific, Uppsala, Sweden) to 110 patients
with a diagnosis of idiopathic anaphylaxis in UK
and found new allergenic sensitizations in half of
the patients studied, which in 20% of the cases
were identified as the cause of the anaphylaxis
with a high likelihood (although it was only reas-
sessed in 50% of those patients). Omega-5-gliadin and
shrimp allergens accounted for 45% of the previously
unrecognized sensitizations. Other newly identified
allergens related to the anaphylaxis were seed storage
proteins, nsLTP and latex allergens. We must bear in
mind that some molecules are poorly represented in
allergen extracts, and therefore the sensitivity of
conventional diagnostic tests (SPT, sIgE) will not allow
a diagnosis.
Therefore, the performance of a multiplex CRD and
sIgE to α-gal, when available, would be very helpful in
the assessment of idiopathic anaphylaxis. If positive, it
may orientate on the triggering allergen; if negative, a
non-IgE mediated mechanism underlying the anaphyl-
axis may be more likely.
Latex allergy
Correct identification of latex-sensitized patients with
true latex allergy is of major importance as these patients
have an increased risk for potentially severe reactions dur-
ing medical procedures. On the other hand, identification
of irrelevant latex-sensitization due to cross-reactive aller-
gens would avoid a wrong diagnosis of latex allergy, prevent
unnecessary latex-avoidance measures and reduce health-
care costs.
Latex allergens Hev b 1, Hev b 3, Hev b 5 and Hev b
6 are currently considered markers of genuine latex
sensitization. On the other hand, studies on CRD of
latex allergy have consistently shown that the majority
of latex-sensitized persons, asymptomatic upon latex
exposure, have a profilin sensitization with monosensi-
tization to Hev b 8 [35,36]. Typically, these patients
have a positive sIgE against latex, but are negative in
SPT and do not show latex-specific symptoms upon
contact with latex-containing material [37]. Haeberle
et al. [38] and Quercia et al. [39] have reported that
these patients can undergo major surgery in normal
surgical setting without any consequences. Thus, Hev
b 8 has been proposed as a marker of asymptomatic
latex sensitization.
In the particular case of hymenoptera venom allergy
with positive sIgE to latex, sensitization to CCD should be
Figure 3 Allergens associated to higher versus lower risk of anaphylaxis. CCD: Cross-reactive carbohydrate determinants; nsLTP: Non-specific lipid
transfer proteins.
Figure 4 Multiplex CRD interpretation flow-chart. AIT: Allergen immunotherapy; CCD: Cross-reactive carbohydrate determinants; CEFA: cofactor
enhanced food allergy; NSAID: non-steroidal anti-inflammatory drugs; nsLTP: Non-specific lipid transfer proteins; OAS: oral allergy syndrome; PR-10:
pathogenesis-related protein family 10 (Bet v 1- homologues); TLP: thaumatin-like proteins.
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Figure 5 Hypothetical scheme representing the potential use of CRD. Represented by spheres are the allergic conditions in which
molecular diagnosis may be of potential value, illustrating the potential overlap between different clinical reactions. Recommended
components to be tested are listed; multiplexed CRD would be of special interest in idiopathic anaphylaxis and polysensitized patients.
CEFA: cofactor-enhanced food allergy; HVA: hymenoptera venom allergy; IA: idiopathic anaphylaxis; M-CRD: multiplex CRD; nsLTP:
non-specific lipid transfer proteins.
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CCD responsible for non-clinically relevant positive sero-
logical test to commercial latex extract [40].
As a practical approach, in case of unequivocal clinical
history of latex allergy with positive NRL-SPT and/or
sIgE it may not be necessary to perform a CRD study
since no association between allergens and severity of
reactions has been identified so far.
Although cross-reactivity between several latex allergens
(Hev b 5, Hev b 6, Hev b 7, Hev b 11, Hev b 13,…) and
plant-food allergens has been described to explain the so
called “latex-fruit syndrome”, to date there are no risk-
assessment studies evaluating molecular sensitization pro-
files and clinical food-allergy in latex allergic patients.Polysensitization to inhalant and food allergens
One of the biggest challenges for the allergist is to con-
front the patient with positive SPT to several pollen and
food allergens. In this scenario CRD may be of major
usefulness, improving the resolution of conventional
diagnosis by adding information on the genuine primary
sensitizers to distinguish them from sensitization due to
cross-reactivity [41] (Figures 1 and 2). With regard to
poly-pollen sensitization, this information may be rele-
vant for prescribing AIT as discussed before.Polysensitization to animal dander (cat, dog and horse)
can in part be explained by cross-reactive lipocalins and
albumins [7]. Can f 6 (dog lipocalin) is a likely candidate
for cross-species sensitization with cat (Fel d 4) and
horse (Equ c 1) [42] with clinical relevance [43]. Serum
albumin is also implicated in cross-reactivity in the so-
called cat-pork syndrome, where patients developing a
cat serum albumin IgE response react upon pork meat
ingestion [44].
Allergic reactions to fruits and vegetables can result
from a primary sensitization to food or to inhalant
allergens. Usually, cross reactivity is attributable to labile
allergens (e.g., PR-10 and profilins) and associated with
mild oral reactions [45], while heat and proteolysis-
resistant allergens that primary sensitize through the
oral route, are associated with systemic reactions in
addition to local reactions (e.g. seed storage proteins and
nsLTP) [2]. Sensitization to CCD in food or venoms
does not have remarkable clinical relevance, and the pri-
mary sensitization may derive from either pollen or
venoms. [46] Since purified native allergens may express
carbohydrates (while recombinants do not), determin-
ation of sIgE to MUXF3 (a type of CCD) should be per-
formed to rule out irrelevant sensitization to CCD in
case of positive sIgE to purified native glycosilated aller-
gens without clinical symptoms [47].
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Risk assessment
Since the first study on CRD in apple allergy across
Europe [48], where it was demonstrated that sensitization
to apple nsLTP (Mal d 3) was associated with a 7 fold risk
of anaphylaxis compared to sensitization apple Bet v 1
homologue (Mal d 1), nsLTP have been considered markers
of severe allergic reactions. However, studies on patterns
of nsLTP sensitization in Mediterranean patients have
shown that the clinical expression is variable, ranging from
asymptomatic sensitization to severe anaphylaxis [49,50],
possibly modulated by pollen allergen co-sensitization
and the presence of cofactors [51]. A predictive pattern of
clinical expression in nsLTP-sensitized patients has not yet
been elucidated.
Bet v 1 homologues are considered markers of mild al-
lergic reactions to fruits and vegetables due to cross-
reactivity with birch pollen. However, although not fre-
quent, some anaphylactic reactions to apple in patients
sensitized to PR10-proteins have been reported [52]. In
the particular case of soya allergy, Gly m 4 (the Bet v 1
related allergen in soya) has been related to severe, gen-
eralized symptoms [53].
Seed storage proteins from nuts and soya have been
associated with higher risk of severe allergic reactions
[54]. In the case of peanut, Ara h 2 seems to be the best
predictor of peanut allergy, reducing the need for peanut
challenges by at least 50% [55]. Altogether, Ara h 1, Ara
h 2 and Ara h 3 have been associated with severe symp-
toms, although anaphylactic reactions have been de-
scribed in patients negative for these allergens [56].
Sensitization to Cor a 9 and Cor a 14 have been re-
ported to be highly specific for hazelnut allergic patients
with objective symptoms in DBPCFCs and proposed as
markers for a more severe hazelnut allergic phenotype
[57]. Similarly, in patients with soybean allergy, Gly m 5
and Gly m 6 have been proposed as potential markers
for severe allergic reactions [58].
Altogether, CRD may be a useful tool for stratifying
patient’s risk for severe reactions but it is important to
bear in mind that the risk of developing anaphylaxis de-
pends not only on the allergen sensitization pattern, but
also on the avidity and affinity of immunoglobulins to
bind the allergen, the route of application, characteristics
of the allergen and the presence of cofactors [27]. Figure 3
depicts those allergens that have been associated to higher
versus lower risk of anaphylaxis.
Identification of unanticipated allergen triggers
The sensitization profile also has major implications
regarding the scope of types of plant foods that may
trigger symptoms. Sensitization to seed storage proteins
will limit allergic symptoms to nuts and occasionally
to legumes [59], while sensitization to PR-10, nsLTP [60]or thaumatin-like proteins (TLP) [61] is frequently asso-
ciated with symptoms with multiple fruits, vegetables,
etc. However, currently there are no markers to predict
the natural history; these patients should be followed-
up and informed about the potential future reactions,
although there is no evidence to advice avoidance.
When to use singleplex or multiplex CRD
Single allergens for CRD can be either recombinant (r)
or natural purified (n) and sIgE can be measured either
in singleplex or multiplex platforms. Depending on the
aim of the CRD (guidance of AIT, polysensitization, latex
allergy, etc.), the availability in each country and the
complexity of the case, the clinician will choose one or
the other. In general, for complex cases of multiple sen-
sitizations to respiratory and food allergens as well as for
idiopathic anaphylaxis study, a multiplex CRD should be
performed. The clinician should be aware of benefits
and pitfalls of molecular multiplex platforms before initi-
ating a study. Multiplex assays allow up to 112 allergen
assays in parallel with the use of very low serum quan-
tities and no interference from very high total IgE but
are less sensitive than singleplex assays and less appropriate
for monitoring sensitization [4]. A guideline to help the
allergy specialist to interpret multiplex molecular allergy
diagnosis is proposed (Figure 4).
Conclusions
The vast information provided by molecular allergy needs a
structured approach in order to be adequately interpreted.
There is a need to evaluate single positivities and negativ-
ities, but also to appraise “the big picture” with perspective
(Figure 5). When making decisions on this information,
one has to bear in mind what is included in the tests and
what is missing. It is needed that we understand that not all
allergenic sources are present in the available arrays, but
that the most important allergenic protein families are. This
is relevant both when searching for a culprit allergen as
when ruling out possible causes of certain reactions.
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